[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Retreat Late Afternoon",
    "summary": "Health care stocks declined late Monday afternoon, with the NYSE Health Care Index shedding 0.9% and",
    "url": "https://finnhub.io/api/news?id=58d11400075130db21e5d696bc9998dbff228414b5fc974b8d0ef9c233651a7b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750103454,
      "headline": "Sector Update: Health Care Stocks Retreat Late Afternoon",
      "id": 135317019,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Health care stocks declined late Monday afternoon, with the NYSE Health Care Index shedding 0.9% and",
      "url": "https://finnhub.io/api/news?id=58d11400075130db21e5d696bc9998dbff228414b5fc974b8d0ef9c233651a7b"
    }
  },
  {
    "ts": null,
    "headline": "Roche: Despite Venclexta Study Failure, PD Program Is Another Growth Avenue",
    "summary": "Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click here to find out why RHHBY is a Buy.",
    "url": "https://finnhub.io/api/news?id=7d4963bbb39d214782641e0fb4dac9b0bfa65d3840012810d5045f4439775623",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750093532,
      "headline": "Roche: Despite Venclexta Study Failure, PD Program Is Another Growth Avenue",
      "id": 135310971,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2205687057/image_2205687057.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click here to find out why RHHBY is a Buy.",
      "url": "https://finnhub.io/api/news?id=7d4963bbb39d214782641e0fb4dac9b0bfa65d3840012810d5045f4439775623"
    }
  },
  {
    "ts": null,
    "headline": "EHA 2025: Genmab and AbbVie’s Epkinly outpaces BiTE rivals in r/r DLBCL trial",
    "summary": "Epkinly (epcoritamab) is a subcutaneously delivered CD3×CD20 BiTE that secured FDA accelerated approval in 2023 for r/r DLBCL.",
    "url": "https://finnhub.io/api/news?id=4adde2c5d93dd343bdede541393d7773858b88c43ef2f3e2d8c4504bdc850b18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750081591,
      "headline": "EHA 2025: Genmab and AbbVie’s Epkinly outpaces BiTE rivals in r/r DLBCL trial",
      "id": 135302913,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Epkinly (epcoritamab) is a subcutaneously delivered CD3×CD20 BiTE that secured FDA accelerated approval in 2023 for r/r DLBCL.",
      "url": "https://finnhub.io/api/news?id=4adde2c5d93dd343bdede541393d7773858b88c43ef2f3e2d8c4504bdc850b18"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why AbbVie (ABBV) is a Strong Value Stock",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=2c6a2b4e8a46266a180534998b21e15aa04b823e2f9a6a63d32d6dc7bf3dceaa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750081203,
      "headline": "Here's Why AbbVie (ABBV) is a Strong Value Stock",
      "id": 135317029,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=2c6a2b4e8a46266a180534998b21e15aa04b823e2f9a6a63d32d6dc7bf3dceaa"
    }
  },
  {
    "ts": null,
    "headline": "5 Large Drug Stocks That Are Poised to Ride on Sector Recovery",
    "summary": "In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.",
    "url": "https://finnhub.io/api/news?id=654dcc3ef1c2a828a9daf3effc8177dfd9f1b913b552cd45be3e62a40029cd71",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750079160,
      "headline": "5 Large Drug Stocks That Are Poised to Ride on Sector Recovery",
      "id": 135305468,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.",
      "url": "https://finnhub.io/api/news?id=654dcc3ef1c2a828a9daf3effc8177dfd9f1b913b552cd45be3e62a40029cd71"
    }
  },
  {
    "ts": null,
    "headline": "Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?",
    "summary": "JNJ's Innovative Medicines unit shows a growth trend, defying Stelara LOE and the negative impact of the Part D redesign.",
    "url": "https://finnhub.io/api/news?id=5f33d906adc1b592893ec7877c438cb630f84195085347af1aa3d983c53d2697",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750078800,
      "headline": "Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?",
      "id": 135314386,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "JNJ's Innovative Medicines unit shows a growth trend, defying Stelara LOE and the negative impact of the Part D redesign.",
      "url": "https://finnhub.io/api/news?id=5f33d906adc1b592893ec7877c438cb630f84195085347af1aa3d983c53d2697"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes",
    "summary": "AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) did not meet the primary endpoint of overall survival (OS) with a hazard ratio (HR) of 0.908; stratified log-rank, p=0.3772. No new safety signals were observed.1 Results from the VERONA trial will be available in a future medical congress and/or publication. Any patients who received venetoclax in co",
    "url": "https://finnhub.io/api/news?id=6c918ee11d75291adb2e5c77237be6692e24d100d8147223b38985287f34a7e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750078800,
      "headline": "AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes",
      "id": 135302915,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) did not meet the primary endpoint of overall survival (OS) with a hazard ratio (HR) of 0.908; stratified log-rank, p=0.3772. No new safety signals were observed.1 Results from the VERONA trial will be available in a future medical congress and/or publication. Any patients who received venetoclax in co",
      "url": "https://finnhub.io/api/news?id=6c918ee11d75291adb2e5c77237be6692e24d100d8147223b38985287f34a7e3"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: trial fails in myelodysplastic syndrome",
    "summary": "AbbVie announces that the global Phase 3 VERONA trial evaluating venetoclax, in combination with azacitidine, for the treatment of newly diagnosed high-risk myelodysplastic syndrome did not meet its...",
    "url": "https://finnhub.io/api/news?id=7a985e0c15405de2a00b2b7cc61f93acb3a34ff0427b0c988a9b575bc76a930d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750067801,
      "headline": "AbbVie: trial fails in myelodysplastic syndrome",
      "id": 135301120,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie announces that the global Phase 3 VERONA trial evaluating venetoclax, in combination with azacitidine, for the treatment of newly diagnosed high-risk myelodysplastic syndrome did not meet its...",
      "url": "https://finnhub.io/api/news?id=7a985e0c15405de2a00b2b7cc61f93acb3a34ff0427b0c988a9b575bc76a930d"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's Venetoclax Doesn't Meet Primary Endpoint in Trial for Higher-Risk Myelodysplastic Syndrome Treatment",
    "summary": "By Denny Jacob AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall...",
    "url": "https://finnhub.io/api/news?id=4f542e5af96e66f70fd2d5362ac85bac24ebbc66b9270682ae65e7acb325448a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750067476,
      "headline": "AbbVie's Venetoclax Doesn't Meet Primary Endpoint in Trial for Higher-Risk Myelodysplastic Syndrome Treatment",
      "id": 135301062,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "By Denny Jacob AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall...",
      "url": "https://finnhub.io/api/news?id=4f542e5af96e66f70fd2d5362ac85bac24ebbc66b9270682ae65e7acb325448a"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie says blood cancer drug fails late-stage trial",
    "summary": "June 16 - AbbVie said on Monday its treatment for a group ofblood cancers failed to meet the main goal of overall survivalin a late-stage trial. The company was testing...",
    "url": "https://finnhub.io/api/news?id=aa49ece832663a7daa6c53b8aef8b5bd03f2505e25d876519f4a514c717dad9a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750065924,
      "headline": "AbbVie says blood cancer drug fails late-stage trial",
      "id": 135300867,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "June 16 - AbbVie said on Monday its treatment for a group ofblood cancers failed to meet the main goal of overall survivalin a late-stage trial. The company was testing...",
      "url": "https://finnhub.io/api/news?id=aa49ece832663a7daa6c53b8aef8b5bd03f2505e25d876519f4a514c717dad9a"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Margin Clarity, Dividend Durability Awaited",
    "summary": "AbbVie's top line is stable post-Humira, with Skyrizi and Rinvoq driving growth, but margin recovery remains uncertain and slow. Read more on ABBV stock here.",
    "url": "https://finnhub.io/api/news?id=772566440ae13338f3f546e3896791924cb4a4c90a5627ef7ed8ea4114f089f8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750050325,
      "headline": "AbbVie: Margin Clarity, Dividend Durability Awaited",
      "id": 135297281,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2176459835/image_2176459835.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie's top line is stable post-Humira, with Skyrizi and Rinvoq driving growth, but margin recovery remains uncertain and slow. Read more on ABBV stock here.",
      "url": "https://finnhub.io/api/news?id=772566440ae13338f3f546e3896791924cb4a4c90a5627ef7ed8ea4114f089f8"
    }
  },
  {
    "ts": null,
    "headline": "1 Cash-Producing Stock for Long-Term Investors and 2 to Steer Clear Of",
    "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
    "url": "https://finnhub.io/api/news?id=0b125923223aabb1dc608990fb203bd0493c6e0e941f154d15186e2fdf701149",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750049187,
      "headline": "1 Cash-Producing Stock for Long-Term Investors and 2 to Steer Clear Of",
      "id": 135300551,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
      "url": "https://finnhub.io/api/news?id=0b125923223aabb1dc608990fb203bd0493c6e0e941f154d15186e2fdf701149"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Moves From Blockbuster Loss To Market Domination",
    "summary": "From migraine to Parkinsonâs and obesity, AbbVie is building dominant franchises across multiple high-growth areas. Read why ABBV stock is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=8dbafb6a4f100c2d340a532df2ee2e50d0ad1421490a8256a5b8be01ae716f5e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750037350,
      "headline": "AbbVie Moves From Blockbuster Loss To Market Domination",
      "id": 135290339,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "From migraine to Parkinsonâs and obesity, AbbVie is building dominant franchises across multiple high-growth areas. Read why ABBV stock is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=8dbafb6a4f100c2d340a532df2ee2e50d0ad1421490a8256a5b8be01ae716f5e"
    }
  }
]